
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
San Francisco - Dermatologists are currently fine-tuning their use of UVB phototherapy for specific applications in order to reduce the risk of burns, minimize patients' cumulative exposure to UVB light, and optimize patient responses.